Indian synthetic biology company StrainX Bioworks has raised $13 million as it exits stealth and moves into commercialization, with plans to supply high-value food and nutritional ingredients to global markets through precision fermentation.
The round was led by Prime Venture Partners and Leo Capital, with participation from Good Startup, Sparrow Capital, Sun Icon Ventures, Dholakia Ventures, and WindT (IIT Delhi) Angels. Good Startup, a fund focused exclusively on biology-first deep-tech companies, makes its first India investment with this deal.
Full-stack model sets it apart
Founded by IIT Delhi alumni Akshay Mittal and Dr. Alok Malaviya, StrainX has spent roughly three years building capabilities across strain engineering, process development, scale-up, downstream processing, and commercialization internally. The specific molecules in its portfolio have not been disclosed, with parts of it remaining in stealth.
The decision to build manufacturing in-house rather than rely on contract fermentation partners reflects both strategic intent and practical necessity: precision fermentation infrastructure in India has historically been oriented toward pharma, leaving a gap for food-grade ingredient production.
The company has operationalized 10,000-liter fermentation capacity with repeatable results, a facility designed modularly toward 100,000-liter scale. One molecule has received US self-GRAS status. The team numbers more than 100 people, including around 35 scientists and 15 PhDs.
Mittal stated, “StrainX is building a full-stack precision fermentation company from India. We develop our own technology, do our own scale-up, build our own manufacturing, and take products through development and commercialization ourselves. We believe this level of integration is critical for owning innovation, creating meaningful cost advantages, and building long-term value in food ingredients.”
Investor confidence amid a cooling market
Investor interest in precision fermentation has cooled in Western markets following a difficult 2023 and 2024, making the raise a signal of continued conviction in emerging market biotech infrastructure. “StrainX stood out to us because it combines two things that are rarely found together in biotech: serious science and sharp business execution,” said Brij Bhushan, Managing Partner at Prime Venture Partners.
Dr. Malaviya added, “Our focus has been to build deep technical capability with a clear path to commercialization and scale. The real challenge is not only proving the science, but translating it into a scalable and commercially viable process.”
